The genetic inhibition of MRPs, such as MRPL35, may prevent NSCLC growth by blocking the dependence of cancer cells on glutamine metabolism, which may provide a novel insight into the development of molecular targeted therapy for NSCLC patients. The gene discussed is MRPL35; the disease is non-small cell lung carcinoma.